Barton Ford Haynes is an American physician and immunologist internationally recognized for work in T-cell immunology, retrovirology, and HIV vaccine development.
[4][5] The "big science" approach of the CHAVI grant enabled the following scientific discoveries by the CHAVI team: 1) the delineation of HIV-1 transmitted/founder viruses that are responsible for the transmission of HIV/AIDS; 2) the discovery of host tolerance mechanisms that limit the induction of broad neutralizing antibodies in HIV-1 infection; 3) the fine mapping and delineation of the immunological events that transpire during the earliest days of HIV-1 infection; 4) the discovery of new genes and gene mutations/duplications that contribute to HIV-1 control and progression; 5) the design of mosaic T cell and B cell Env vaccine candidates to overcome HIV diversity; 6) the discovery of the immune correlates of risk of infection in the RV144 trial;[6] 7) the isolation of rare broad neutralizing HIV antibodies and their ancestor antibodies; and 8) the development of a new strategy for vaccine development called B Cell Lineage Immunogen Design.
After conducting research for five years at the National Institute of Allergy and Infectious Diseases from 1975 to 1980, Haynes returned to Duke as a member of the faculty in the department of medicine in 1980.
[12] He served as Chief of the Division of Rheumatology, Allergy and Clinical Immunology from 1987 to 1995, and as chair of the department of medicine from 1995 to 2002 at Duke University Medical Center.
Haynes served on the NIAID Blue Ribbon Committees on Bioterrorism and Emerging Infections held in February and October 2002.